Company intelligence / Profile preview
Hangzhou Bangshun Pharmaceutical
Hangzhou, Zhejiang, Chinabiosunpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program (bewintinib) has reached NDA/BLA (regulatory filing) for myelofibrosis. Additional programs in hematology, oncology, and immune diseases are at IND or earlier clinical stages[1][3].
- Therapeutic areas
- HematologyOncology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Hangzhou Guangliang Biomedical
Beyond the preview
Go deeper on Hangzhou Bangshun Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Bangshun Pharmaceutical.